claim: antibody testing will limit the power and accuracy of covid-19-prevention trials
evidence_1: knowing that someone seroconverts and becomes immune during the trial despite having no symptoms could, for instance, prove to be a more optimal outcome than simply preventing infection and the development of immunity altogether, as has been observed in some patients receiving chemoprophylaxis for influenza8.", "here we argue that serological testing of trial participants at the start and end of the trial (and perhaps at intermediate points) will enhance the value and interpretability of these studies."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )